Teva Pharmaceutical Industries Limited (TEVA) |
| 32.365 -0.105 (-0.32%) 01-14 13:18 |
| Open: | 31.95 |
| High: | 32.855 |
| Low: | 31.92 |
| Volume: | 3,745,686 |
| Market Cap: | 37,117(M) |
| PE Ratio: | 53.06 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 39.03 |
| Resistance 1: | 33.42 |
| Pivot price: | 31.86 |
| Support 1: | 30.39 |
| Support 2: | 28.52 |
| 52w High: | 33.42 |
| 52w Low: | 12.47 |
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
| EPS | 0.610 |
| Book Value | 6.320 |
| PEG Ratio | 0.00 |
| Gross Profit | 7.304 |
| Profit Margin (%) | 4.25 |
| Operating Margin (%) | 23.79 |
| Return on Assets (ttm) | 5.5 |
| Return on Equity (ttm) | 9.7 |
Wed, 14 Jan 2026
Teva Is No Longer A Turnaround Story—It's A Growth One (NYSE:TEVA) - Seeking Alpha
Mon, 12 Jan 2026
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Zacks Investment Research
Mon, 12 Jan 2026
Why Is TEVA Stock Rising Pre-Market Today? - Stocktwits
Mon, 12 Jan 2026
Teva Pharmaceutical Industries (NYSE:TEVA) Issues FY 2025 Earnings Guidance - MarketBeat
Mon, 12 Jan 2026
Teva lines up $500M in Royalty Pharma funding for vitiligo drug - Fierce Biotech
Mon, 12 Jan 2026
Teva inks deal with Royalty Pharma on potential vitiligo drug - The Pharma Letter
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |